Clinical trials: C-peptide
Asthma
Effect of Montelukast on Remodelling Markers in Asthmatic Children
Airway smooth muscle cell layer thickening and sub epithelial fibrosis, key allergen-induced airway remodelling features not modulated by corticosteroids, are reversible by CysLT1 receptor blockade therapy in animals.
- Trial name
- MORACH (NCT00875082)
- Testing
- Montelukast
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Universita di Verona
Achondroplasia
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
- Trial name
- NCT03424018
- Testing
- BMN 111
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 119 people
- Sponsor
- BioMarin Pharmaceutical
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Myocardial Infarction, No Reflow Phenomenon
Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI
To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI.
- Trial name
- VaBiNoR (NCT07132489)
- Testing
- HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio
- Volunteers
- 114 people
- Sponsor
- Assiut University
Type 1 Diabetes (T1D)
PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study
This Phase 3, multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of SAB-142, a fully human anti-thymocyte globulin (h-ATG), in participants aged 5 to 40 years with…
- Trial name
- PRISE-hATG (NCT07670650)
- Testing
- SAB-142
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of Florida
Type1diabetes
Development of Predictive Biomarkers
Investigators aim to further the understanding of the various factors that govern the progression of beta-cell death in individuals recently diagnosed with Type 1 diabetes (T1D).
- Trial name
- NCT03423862
- Testing
- Mixed Meal Tolerance Test
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Medical College of Wisconsin
Type 1 Diabetes, Diabetes, Autoimmune
Characteristics of Young-onset Diabetes in Sub-Saharan Africa (YODA) Study
Type 1 diabetes has been poorly characterised, with very sparse information available in the literature about the characteristics of the disease in Africa.
- Trial name
- YODA (NCT05013346)
- Testing
- No intervention needed
- Where
- 4 sites in Cameroon, South Africa and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Yaounde Central Hospital
Type 1 Diabetes
A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil
The objective of this trial is first to evaluate safety and then the effect on preservation of residual beta cell function also clinical efficacy by treatment with Verapamil in children with recent onset Type 1 diabetes.
- Trial name
- VERADIAB-1 (NCT07199946)
- Testing
- Verapamil (Part A)
- Where
- 2 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- Johnny Ludvigsson
Diabetes Mellitus, Type 1
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100…
- Trial name
- NCT05743244
- Testing
- Abrocitinib 200 MG Oral Tablet, Ritlecitinib
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 78 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)
The Diabetes Prevention Trial of Type 1 (DPT-1) was a multicenter randomized, controlled clinical trial designed to determine whether it is possible to delay or prevent the clinical onset of type 1 diabetes through daily doses of…
- Trial name
- DPT-1 (NCT00004984)
- Testing
- Parenteral Insulin, Close Observation, Oral Insulin
- Where
- 15 sites in United States, Canada
- Volunteers
- 711 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1, Autoimmune Diseases
Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes
A 2-arm randomized Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® (Diamyd) also known as retogatein in individuals at risk of Type 1 diabetes carrying the HLA DR3-DQ2…
- Conditions
- Diabetes Mellitus, Type 1, Autoimmune Diseases, Prevention
- Trial name
- NCT05683990
- Testing
- Diamyd
- Where
- Sweden
- Volunteers
- 5 people
- Sponsor
- Diamyd Medical AB
Achondroplasia
A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia
Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.
- Trial name
- NCT03583697
- Testing
- BMN 111
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 75 people
- Sponsor
- BioMarin Pharmaceutical
Diabetes, Type 1 Diabetes
The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes
The purpose of this study is to determine if the drug Alpha-1 Antitrypsin (AAT, Aralast NP) will preserve beta-cell function and help slow the progression of type 1 diabetes.
- Trial name
- NCT01319331
- Testing
- Alpha 1-Antitrypsin (AAT, Aralast NP)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Colorado, Denver
Achondroplasia
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height.
- Trial name
- NCT03989947
- Testing
- Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 73 people
- Sponsor
- BioMarin Pharmaceutical
Diabetes Mellitus, Diabetes Type 1
ACZ885 in Type 1 Diabetes Mellitus
This study will assess the safety and efficacy of ACZ885 on stimulated C-peptide during a mixed meal test in patients with newly-diagnosed type 1 diabetes mellitus.
- Trial name
- NCT01322321
- Testing
- ACZ885
- Where
- 10 sites in United States, Canada and 2 more
- Sponsor
- Novartis Pharmaceuticals
Islets of Langerhans Transplantation, Diabetes Mellitus
Arginine-stimulated Indication of Early Outcome After Islet Transplantation
Through islet transplantation, functional β-cell mass can be restored. Allogeneic islet transplantation is a treatment modality for a select group of patients with complicated type 1 diabetes mellitus.
- Conditions
- Islets of Langerhans Transplantation, Diabetes Mellitus, Chronic Pancreatitis
- Trial name
- ALADDIN (NCT05540197)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Leiden University Medical Center
Achondroplasia
A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia.
- Trial name
- NCT03197766
- Testing
- BMN 111
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- BioMarin Pharmaceutical
Type 1 Diabetes Mellitus
Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM
This study evaluates early initiation of continuous subcutaneous insulin infusion (CSII) therapy in young children using a novel delivery method in the form of a self-contained, lightweight, and disposable insulin pump unit…
- Trial name
- NCT00476788
- Testing
- Omnipod Insulin Management System
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Noonan Syndrome
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
The purpose of this study in children with Noonan syndrome is to evaluate the effect of 3 doses of vosoritide on growth as measured by AGV after 6 months of treatment.
- Trial name
- NCT06668805
- Testing
- Vosoritide Injection
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 30 people
- Sponsor
- BioMarin Pharmaceutical
Type 1 Diabetes Mellitus
Biomarkers of Type 1 Diabetes in Children and Their Healthy Siblings
This prospective observational cohort study evaluated genetic, immunologic, and environmental factors associated with type 1 diabetes in children.
- Trial name
- NCT07627230
- Where
- Russia
- Volunteers
- 1,034 people, healthy volunteers welcome
- Sponsor
- Privolzhsky Research Medical University